Journal
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
Volume 8, Issue 3, Pages 363-370Publisher
AMER SOC NEPHROLOGY
DOI: 10.2215/CJN.05540512
Keywords
-
Categories
Funding
- National Center for Advancing Translational Sciences of the National Institutes of Health (NIH) [8UL1TR000041]
- University of New Mexico (UNM) Clinical and Translational Science Center
- National Center for Research Resources [5P20RR016480-12]
- National Institute of General Medical Sciences of the NIH [8P20GM103451-12]
- UNM Health Sciences-based Cardiovascular and Metabolic Diseases Signature Program
- NIH [DK-060984, UL1RR024134]
- National Center for Research Resources
Ask authors/readers for more resources
Background and objectives CKD is a common public health problem. Identifying biomarkers adds prognostic/diagnostic value by contributing to an understanding of CKD at the molecular level and possibly defining new drug targets. Metabolomics provides a snapshot of biochemical events at a particular time in the progression of CKD. This cross-sectional metabolomics study ascertained whether plasma metabolite profiles are significantly different in CKD stages 2, 3, and 4. Design, setting, participants, & measurements An analysis of plasma metabolites, using gas and liquid chromatography coupled to mass spectrometry, was conducted on 30 nondiabetic men ages 40-52 years, with 10 participants each in CKD stages 2, 3, and 4 based on their estimated GFR (calculated by the Modified Diet in Renal Disease formula). Participants were recruited in late 2008, and plasma samples were tested at Metabolon Inc and analyzed in 2012. Results Comparison of stage 3/stage 2 identified 62 metabolites that differed (P <= 0.05), with 39 higher and 23 lower in stage 3 compared with stage 2; comparisons of stage 4/stage 2 identified 111 metabolites, with 66 higher and 45 lower; and comparisons of stage 4/stage 3 identified 11 metabolites, with 7 higher and 4 lower. Major differences in metabolite profiles with increasing stage of CKD were observed, including altered arginine metabolism, elevated coagulation/inflammation, impaired carboxylate anion transport, and decreased adrenal steroid hormone production. Conclusions Global metabolite profiling of plasma uncovered potential biomarkers of stages of CKD. Moreover, these biomarkers provide insight into possible pathophysiologic processes that may contribute to progression of CKD. Clin J Am Soc Nephrol 8: 363-370, 2013. doi: 10.2215/CJN.05540512
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available